CoChat
Sign Up
Cited by 159Diabetes Management and ResearchDiabetes Management and EducationDiabetes and associated disorders

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial

Open access
McAuley, Sybil A., Lee, Melissa H., Paldus, Barbora, Vogrin, Sara, de Bock, Martin I., Abraham, Mary B., Bach, Leon A., Burt, Morton G., Cohen, Neale D., Colman, Peter G., Davis, Elizabeth A., Hendrieckx, Christel, Holmes-Walker, D. Jane, Kaye, Joey, Keech, Anthony C., Kumareswaran, Kavita, MacIsaac, Richard J., McCallum, Roland W., Sims, Catriona M., Speight, Jane, Stranks, Stephen N., Sundararajan, Vijaya, Trawley, Steven, Ward, Glenn M., Jenkins, Alicia J., Jones, Timothy W., O’Neal, David N., Australian JDRF Closed-Loop Research Group, O’Neal, David N., McAuley, Sybil A., Lee, Melissa H., Paldus, Barbora, Sims, Catriona M., MacIsaac, Richard J., Ward, Glenn M., Colman, Peter G., Cohen, Neale D., Bach, Leon A., Kumareswaran, Kavita, Stranks, Stephen N., Burt, Morton G., Holmes-Walker, D. Jane, McCallum, Roland W., Kaye, Joey, Speight, Jane, Hendrieckx, Christel, Halliday, Jennifer, Russell-Green, Sienna, Trawley, Steven, Jenkins, Alicia J., Januszewski, Andrzej, Keech, Anthony C., Vogrin, Sara, Sundararajan, Vijaya, Mohammed Husin, Hanafi, Clarke, Philip M., Jones, Timothy W., Davis, Elizabeth A., de Bock, Martin I., Abraham, Mary B., Ambler, Geoff R., Cameron, Fergus J., Fairchild, Jan M., King, Bruce R.·2020·Diabetes Care
DOI 10.2337/dc20-1447
Open this paper in CoChat — free account

Abstract

Objective To investigate glycemic and psychosocial outcomes with hybrid closed-loop (HCL) versus user-determined insulin dosing with multiple daily injections (MDI) or insulin pump (i.e., standard therapy for most adults with type 1 diabetes). Research design and methods Adults with type 1 diabetes using MDI or insulin pump without continuous glucose monitoring (CGM) were randomized to 26 weeks of HCL (Medtronic 670G) or continuation of current therapy. The primary outcome was masked CGM time in range (TIR; 70-180 mg/dL) during the final 3 weeks. Results Participants were randomized to HCL ( n = 61) or control ( n = 59). Baseline mean (SD) age was 44.2 (11.7) years, HbA 1c was 7.4% (0.9%) (57 [10] mmol/mol), 53% were women, and 51% used MDI. HCL TIR increased from (baseline) 55% (13%) to (26 weeks) 70% (10%) with the control group unchanged: (baseline) 55% (12%) and (26 weeks) 55% (13%) (difference 15% [95% CI 11, 19]; P 1c was lower (median [95% CI] difference -0.4% [-0.6, -0.2]; -4 mmol/mol [-7, -2]; P P Conclusions In adults with type 1 diabetes, 26 weeks of HCL improved TIR, HbA 1c , and their sense of satisfaction from managing their diabetes compared with those continuing with user-determined insulin dosing and self-monitoring of blood glucose. For most people living with type 1 diabetes globally, this trial demonstrates that HCL is feasible, acceptable, and advantageous.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc20-1447

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 38 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
McAuley, S. A., Lee, M. H., Paldus, B., Vogrin, S., de Bock, M. I., Abraham, M. B., Bach, L. A., Burt, M. G., Cohen, N. D., Colman, P. G., Davis, E. A., Hendrieckx, C., Holmes-Walker, D. J., Kaye, J., Keech, A. C., Kumareswaran, K., MacIsaac, R. J., McCallum, R. W., Sims, C. M., Speight, J., Stranks, S. N., Sundararajan, V., Trawley, S., Ward, G. M., Jenkins, A. J., Jones, T. W., O’Neal, D. N., Australian JDRF Closed-Loop Research Group, O’Neal, D. N., McAuley, S. A., Lee, M. H., Paldus, B., Sims, C. M., MacIsaac, R. J., Ward, G. M., Colman, P. G., Cohen, N. D., Bach, L. A., Kumareswaran, K., Stranks, S. N., Burt, M. G., Holmes-Walker, D. J., McCallum, R. W., Kaye, J., Speight, J., Hendrieckx, C., Halliday, J., Russell-Green, S., Trawley, S., Jenkins, A. J., Januszewski, A., Keech, A. C., Vogrin, S., Sundararajan, V., Mohammed Husin, H., Clarke, P. M., Jones, T. W., Davis, E. A., de Bock, M. I., Abraham, M. B., Ambler, G. R., Cameron, F. J., Fairchild, J. M., & King, B. R.
ORCID
Venue
Diabetes Care
Publisher
American Diabetes Association
Published
2020-10-14
Volume
43
Issue
12
Pages
3024-3033
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
DOI
10.2337/dc20-1447
OpenAlex
W3092965120
Cited by
158
References
38
Citations by year
2026: 17 · 2025: 24 · 2024: 33 · 2023: 37 · 2022: 30 · 2021: 16 · 2020: 1
FWCI
15.84
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
  • Deakin Research Online (Deakin University) (submittedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • JDRF Australian Type 1 Diabetes Clinical Research Network (3-SRA-2016-351-M-B)
  • National Health and Medical Research Council of Australia (APP1099379)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
type 1 diabetes, hybrid closed-loop insulin delivery, insulin pump therapy, multiple daily insulin injections, continuous glucose monitoring, time in range, glycemic control, HbA1c, diabetes distress, sleep quality, cognitive function, device-related adverse events, adults with type 1 diabetes, diabetes self-management
MeSH terms
Adult, Aged, Blood Glucose, Blood Specimen Collection, Diabetes Mellitus, Type 1, Female, Fingers, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Insulin, Insulin Infusion Systems, Male, Middle Aged, Personal Satisfaction, Blood Glucose Self-Monitoring, Needlestick Injuries

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review